Business Context and Reporting Period
Company: Eyenovia, Inc. (Note: Request metadata listed "Hyperion DeFi, Inc." but the filing is for Eyenovia, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: June 17, 2025
Reporting Period: Events occurring on June 17, 2025, with a private placement closing on June 20, 2025.
The Company entered into a material definitive agreement for a private placement of Series A Non-Voting Preferred Stock and warrants. Proceeds are designated to build a reserve of the HYPE token (native to the Hyperliquid blockchain) and implement a staking program, marking a new cryptocurrency treasury strategy. The Company will continue its existing business, including the development of the Gen-2 Optejet User Filled Device.
Key Financial Metrics and Capital Structure
- Capital Raised: Approximately $50,000,000 aggregate purchase price for 5,128,205 shares of Series A Preferred Stock and associated warrants.
- Debt Restructuring: Fourth Amendment to Loan and Security Agreement with Avenue Capital Management.
- Interest Rate: Reduced from 12.0% to 8.0% (payable half in cash, half in kind).
- Maturity: Extended to July 1, 2028.
- Payment Terms: Interest-only period from July 1, 2025, to January 31, 2027.
- Conversion: Eliminated lender option to convert up to $10.0 million of loans into common stock.
- Pro Forma Share Count: 54,027,429 shares of Common Stock outstanding (assuming full conversion of Preferred Stock and exercise of all warrants).
- Current Share Count: 5,104,355 shares of Common Stock issued and outstanding (post-closing, pre-conversion).
Material Changes Versus Prior Period
- Board Composition: Significant reconstitution of the Board of Directors. Sean Ianchulev, M.D., Charles Mather IV (Chair), and Ram Palanki, Pharm. D., resigned. Hyunsu Jung was appointed as Chief Investment Officer and Director.
- Equity Structure: Issuance of Series A Preferred Stock with a 6% annual dividend (payable in cash or stock) and specific protective provisions regarding mergers, asset sales, and additional indebtedness.
- Debt Terms: Substantial improvement in debt service terms via the Fourth Amendment, including lower interest rates and extended maturity.
- Strategic Pivot: Initiation of a cryptocurrency treasury strategy involving the HYPE token, distinct from prior operational focus.
Guidance, Outlook, and Management Commentary
Management Commentary: The Company intends to use net proceeds to build a HYPE token reserve and implement a staking program while continuing development of its medical device pipeline. The appointment of Hyunsu Jung, a former Portfolio Manager at DARMA Capital, signals a strategic shift toward digital asset management.
Risks and Contingencies:
- Dilution: Significant potential dilution exists due to the conversion of Preferred Stock (3:1 ratio) and the exercise of warrants (200% of convertible shares).
- Beneficial Ownership Limits: Holders are restricted from converting or exercising warrants if it results in ownership exceeding 4.99% (increasable to 19.99% by holder election).
- Regulatory: Securities were sold under Section 4(a)(2) and Rule 506 exemptions; resale requires registration.
Unusual Items: The filing notes the appointment of a new CIO and Director contingent on Hyperion DeFi Holdings, LLC maintaining a 50% stake in underlying common stock for 36 months. If Mr. Jung departs, Hyperion has the right to nominate a replacement.
Investor Verification Checklist
- Verify the exact amount of net proceeds received after deducting placement agent fees and transaction expenses.
- Confirm the specific terms of the HYPE token reserve and staking program, including custody and valuation methodologies.
- Review the Certificate of Designation (Exhibit 3.1) for detailed liquidation preferences and voting rights of the Series A Preferred Stock.
- Assess the impact of the 8.0% interest rate (half in kind) on future cash flow requirements and potential dilution from PIK interest.
- Monitor the timeline for the filing of the registration statement for the resale of securities (required within 20 business days of the agreement).